192 related articles for article (PubMed ID: 35241387)
41. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
Shah MV; Saliba RM; Varma A; Ciurea SO; Oran B; Olson A; Bose P; Bashir Q; Masarova L; Alousi AM; Srour S; Mehta RS; Daver N; Pemmaraju N; Verstovsek S; Champlin RE; Popat UR
Br J Haematol; 2021 Jun; 193(5):1004-1008. PubMed ID: 33821472
[No Abstract] [Full Text] [Related]
42. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Sanber K; Ye K; Tsai HL; Newman M; Webster JA; Gojo I; Ghiaur G; Prince GT; Gondek LP; Smith BD; Levis MJ; DeZern AE; Ambinder AJ; Dalton WB; Jain T
Leuk Lymphoma; 2023 Apr; 64(4):846-855. PubMed ID: 36744656
[TBL] [Abstract][Full Text] [Related]
43. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
[TBL] [Abstract][Full Text] [Related]
44. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
45. Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC.
Kaphan E; Bettega F; Forcade E; Labussière-Wallet H; Fegueux N; Robin M; Peffault De Latour R; Huynh A; Lapierre L; Berceanu A; Marcais A; Debureaux PE; Vanlangendonck N; Bulabois CE; Magro L; Daniel A; Galtier J; Lioure B; Chevallier P; Antier C; Loschi M; Guillerm G; Mear JB; Chantepie S; Cornillon J; Rey G; Poire X; Bazarbachi A; Rubio MT; Contentin N; Orvain C; Dulery R; Bay JO; Croizier C; Beguin Y; Charbonnier A; Skrzypczak C; Desmier D; Villate A; Carré M; Thiebaut-Bertrand A
Transplant Cell Ther; 2023 Jun; 29(6):362.e1-362.e12. PubMed ID: 36849078
[TBL] [Abstract][Full Text] [Related]
46. Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT.
Chen Z; Zhen S; Zhang T; Shen Y; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Chen X; Jiang E; Han M; Feng S
Front Oncol; 2023; 13():1137175. PubMed ID: 37035180
[TBL] [Abstract][Full Text] [Related]
47. Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
Danylesko I; Canaani J; Shimoni A; Fein J; Shem-Tov N; Yerushalmi R; Shouval R; Nagler A
Acta Haematol; 2021; 144(6):613-619. PubMed ID: 34102632
[TBL] [Abstract][Full Text] [Related]
48. Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors.
Sun YQ; Xu LP; Liu KY; Zhang XH; Yan CH; Jin J; Huang XJ; Wang Y
Cancer Commun (Lond); 2021 Apr; 41(4):333-344. PubMed ID: 33566460
[TBL] [Abstract][Full Text] [Related]
49. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Stahl M; DeVeaux M; Montesinos P; Itzykson R; Ritchie EK; Sekeres MA; Majhail N; Barnard J; Podoltsev NA; Brunner AM; Komrokji RS; Bhatt VR; Al-Kali A; Cluzeau T; Santini V; Roboz GJ; Fenaux P; Litzow M; Fathi AT; Perreault S; Kim TK; Prebet T; Vey N; Verma V; Kobbe G; Bergua J; Serrano J; Gore SD; Zeidan AM
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1754-1758. PubMed ID: 29649620
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
Khan M; Siddiqi R; Gangat N
Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
[TBL] [Abstract][Full Text] [Related]
51. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
Yogarajah M; Tefferi A
Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
[TBL] [Abstract][Full Text] [Related]
52. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
53. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.
Zhou S; Tremblay D; Hoffman R; Kremyanskaya M; Najfeld V; Li L; Moshier E; Mascarenhas J
Acta Haematol; 2021; 144(1):48-57. PubMed ID: 32160610
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
Oh SB; Park SW; Chung JS; Lee WS; Lee HS; Cho SH; Choi YS; Lim SN; Shin HJ;
Ann Hematol; 2017 Nov; 96(11):1801-1809. PubMed ID: 28828639
[TBL] [Abstract][Full Text] [Related]
55. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
56. Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia.
Ciftciler R; Demiroglu H; Buyukasık Y; Aksu S; Goker H
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e205-e212. PubMed ID: 30665867
[TBL] [Abstract][Full Text] [Related]
57. Management of advanced phase myeloproliferative neoplasms.
Marcellino B; Mascarenhas J
Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
[TBL] [Abstract][Full Text] [Related]
58. Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.
Wang ZY; Gao WH; Zhao HJ; Yin CR; Wang ZW; Tian L; Wang L; Wang LN; Jiang JL; Devillier R; Wan M; Wang JM; Huang PP; Blaise D; Hu J
Acta Haematol; 2022; 145(4):419-429. PubMed ID: 35231903
[TBL] [Abstract][Full Text] [Related]
59. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
[TBL] [Abstract][Full Text] [Related]
60. Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.
Saha C; Attwell L; Harrison CN; McLornan DP
Blood Rev; 2022 Sep; 55():100947. PubMed ID: 35241294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]